Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies

Commentary
Video

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC discussed her talk on preparing for gene therapy administration.

“It is hard to understand the gravity of these medicines, because we always focus on such positive outcomes. But there's a dark side to it. And it's scary. There are side effects and it's hard to sometimes convey that. So, one of the challenges is that we have is to make sure that the patients understand what they're signing up for, that there is a risk of death, that there is a risk of other serious injuries and that they can be admitted to the hospital for some very serious potential side effects."

As gene therapies enter the clinical space and become more common, it has become paramount to examine and standardize the logistics of delivering gene therapies, including interdepartmental collaboration in centers delivering these therapies as well as informed consent and preparing patients and families for what gene therapy entails.

Leigh Ramos-Platt, MD, Medical Director, Muscular Dystrophy Association Neuromuscular Clinic and attending physician, Division of Neurology, Children’s Hospital Los Angeles, and Clinical Professor of Neurology and Pediatrics, Keck School of Medicine, University of Southern California (USC), gave a talk around this topic at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, held March 3-6, in Orlando, Florida.

CGTLive® spoke with Ramos-Platt to learn more about the talk and the greater session on post-gene therapy monitoring. She stressed the importance of making sure that patients and families of all backgrounds be able to access these lifesaving therapies, but are also adequately prepared for them. She also shared that across talks in the session, communication was most often identified as the most important factor in the post-gene therapy time period.

REFERENCE
Ramos-Platt L. DMD Gene Therapy Day Of: Institutional and Patient/Family Readiness- When We Were Not a Trial Site. Presented at: 2024 MDA Clinical and Scientific Conference; March 3-6; Orlando, FL.
Recent Videos
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Related Content
© 2025 MJH Life Sciences

All rights reserved.